Clinicopathological Characteristics and Prognosis of Remnant Gastric Cancer by Lee, Sang Bong et al.
Copyrights © 2010 by The Korean Gastric Cancer Association www.jgc-online.org
Original Article
Clinicopathological Characteristics and Prognosis 
of Remnant Gastric Cancer
Sang Bong Lee, Jae Hun Kim, Dae Hwan Kim, Tae Yong Jeon, Dong Heon Kim, Gwang Ha Kim
1, and Do Youn Park
2
Department of Surgery, Postgraduate School of Medicine, Pusan National University, Busan, Korea, 
1Internal Medicine, Postgraduate School of 
Medicine, Pusan National University, Busan, Korea, 
2Pathology, Postgraduate School of Medicine, Pusan National University, Busan, Korea
Purpose: The long-term survival rate of gastric cancer patients after surgery has recently increased as a result of making an early diagno-
sis of gastric cancer. Therefore, the incidence of remnant gastric cancer is increasing. This study was performed to evaluate the clinico-
pathological characteristics and prognosis of patients with remnant gastric cancer. 
Materials and Methods: From January 2005 to December 2009, twenty-nine patients with remnant gastric cancer and who under-
went surgery at Pusan National University Hospital were enrolled in this study. We retrospectively reviewed and analyzed their medical 
records. We also divided them into two groups: the remnant gastric cancer (RGC)-B group (first operation for benign disease) and the 
RGC-M group (first operation for malignant disease).
Results: The RGC-B group included ten patients and the RGC-M group included nineteen patients. The mean interval between the first 
and second operations was 17 years. The curative resection rate was 93.1% (27/29). The postoperative complication rate was 20.7% 
(6/29) and there was no perioperative mortality. Ten (37%) of twenty-seven patients experienced recurrence after curative resection and 
eight patients (27.6%) expired due to aggravation of remnant stomach cancer. An advanced TNM stage and non-curative resection were 
the negative prognostic factors for survival for patients with remnant stomach cancer (P=0.0453 and P<0.001). The RGC-M group 
showed a shorter interval (P<0.001) and the RGC-B group had more advanced TNM stage (P=0.003).
Conclusions: Long-term follow-up should be considered not only for patients who undergo an operation for malignant disease, but also 
for the patients who underwent an operation for benign disease. When remnant gastric cancer is diagnosed, curative resection is essen-
tial to improve the survival.
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Introduction
Remnant gastric cancer is generally defined as cancer that 
has developed in the remnant stomach 5 years after gastrectomy. 
However, in many recent reports, remnant gastric cancer has been 
defined as cancer that has developed in the remnant stomach af-
ter partial gastrectomy regardless of the disease or the operative 
methods used for gastrectomy.(1,2) With the development of the 
medication for treating gastric ulcer, partial gastrectomy for benign 
disease is on the decrease, and so remnant gastric carcinoma that 
develops after surgery for benign diseass is also on the decrease. 
Nonetheless, on account of performing regular endoscopic exami-
nation, the rate of detecting early gastric cancer has recently in-
creased, and so the long-term survival after surgery has increased. 
As a consequence, remnant gastric cancer after partial gastrectomy 
for malignant diseases is on the increase. In recent studies, the 
incidence of remnant gastric cancer that developed after distal gas-
trectomy for gastric cancer has been reported to be 1~2% of all the 
gastric cancer patients.(1,3)
It has been reported that for patients with remnant gastric can-
cer, there is a high stage of disease at the time of diagnosis, lymph Lee SB, et al.
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node metastasis is abundant and the rate of curative resection is low 
because of the frequent invasion to adjacent organs and so prog-
nosis is poor.(3,4) Therefore, it is very important to understand the 
characteristics of remnant gastric cancer and to determine its prog-
nostic factors in order to decide on the treatment methods. There 
are only a small number of studies that have reported on remnant 
gastric cancer.
We studied the clinicopathological characteristic of patients who 
underwent surgery for remnant gastric cancer, and we suggest a 
treatment strategy based on the results.
Materials and Methods
The study was conducted on 29 patients who were diagnosed 
as having remnant gastric cancer at our Department of Surgery, 
Pusan University Hospital, from January 2005 to December 2009. 
The preoperative data of the patients (age, gender, the disease at 
the time of the first operation, the operative methods at the time of 
the first operation, the interval from the first operation to the diag-
nosis of remnant gastric cancer), the operative data (the operative 
methods for remnant gastric cancer, whether radical resection was 
performed, whether combined resection was performed at the time 
of operation, operation time, whether transfusion was performed, 
and hospitalization period) and the postoperative data (the location 
of the remnant gastric cancer, the histological classification, size 
and TNM stage, the presence or absence of lymphovascular inva-
sion, the presence or absence of perineral invasion, the follow-up 
period, recurrence and death) were analyzed retrospectively. 
In regard to surgery, after abdominal incision, total gastrectomy 
with lymphadectomy more than D2 and Roux-en-Y anastomosis 
were performed in all the patients. At the time of lymphadenec-
tomy, lymphadenectomy for the 19th lymph node station (the 
infradiaphragmatic nodes) and the 20th lymph node station (the 
esophageal hiatal nodes) was included for all the patients. Except 
for the patients with suspected metastasis according to the pre-
operative examinations or that was macroscopically determined 
during surgery, lymphadenectomy for the 13th lymph node sta-
tion (the retropancreatic nodes) and the 16th lymph node station 
(the paraaortic nodes) was not performed. For the patients who 
underwent Billroth-I anstomosis during their previous surgeries, 
the duodenum was dissected from the pancreas and subsequently 
a portion of the duodenum was resected, and lymphadenectomy 
for the 17th lymph node station (the anterior pancreatic nodes) was 
performed. For the patients who underwent Billroth II anastomosis 
and Roux-en-Y anastomosis, from the anastomotic site, at least 10 
cm the ileum was resected together with the ileal mesenteric lymph 
nodes. For the patients whose remnant gastric cancer was located 
near the esophagogastric junction, the esophaseal hitus was incised 
and lymphadenectomy for the 110th (lower paraesophageal nodes) 
and the 111th lymph node (supradiaphragmatic nodes) stations was 
performed.
The location of remnant gastric cancer was divided to invasion 
to the anastomotic site, locations other than the anastomotic site, 
and the entire remnant stomach. The TNM stage was classified 
according to the American Joint Committee on Cancer (AJCC), 
7th edition. The histological classification was classified to the dif-
ferentiated group (papillary, well differentiated and moderately 
differentiated carcinoma) and the undifferentiated group (poorly 
differentiated, mucinous and signet ring cell carcinoma). According 
to Lauren’s classification, the cancers were classified to the intes-
tinal type and the diffuse type. In addition, in our study, according 
to the disease at the time of the first operation, the patients were 
divided to the patient group who underwent partial gastrectomy for 
benign diseases (RGC-B) and the patient group who underwent 
partial gastrectomy for malignant diseases (RGC-M), and their 
clinicopathological characteristics were compared and analyzed. 
In addition, the factors affecting the survival rate of all the patients 
were analyzed.
SPSS for Windows (ver. 12.0, SPSS Inc., Chicago. IL. USA) was 
applied for statistical analysis. For the comparison of the RGC-B 
and the RGC-M, the Mann-Whitney U-test and Fisher's exact 
test were performed. Kaplan-Meier Methods were applied for the 
analysis of the survival rate. P-values＜0.05 were considered to be 
statistically significant.
Results
1. The clinicopathological characteristics of the total 
patients
The clinicopathological characteristics of all 29 patients who 
underwent surgery for remnant gastric cancer at our hospital are 
shown in Table 1. The clinicopathological characteristics of the 10 
recurrent patients of the 27 patients who underwent curative resec-
tion are shown in Table 2. The RGC-B patient group was 10 pa-
tients, and the RGC-M patient group was 19 patients. Twenty seven 
patients (93.1%) received curative resection and 2 patients received 
only palliative resection because of intraperitoneal metastasis. An 
average of 21 lymph nodes were retrieved for postsurgical histo-Remnant Gastric Cancer
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logical tests. Combined resection was performed in 12 patients. For 
D2 lymphadenectomy, splenectomy was performed on 6 patients. 
In 4 patients, invasion to the transverse colon was macroscopically 
suspected and so segmental resection was performed. Nonetheless, 
only 2 patients showed invasion on the histology exam. In addi-
tion, hepatic invasion was suspected in 2 patients and so hepatic 
wedge resection was performed, yet invasion was not detected by 
the histological exam. Postoperative complications were detected in 
6 patients (20.7%). Four patients developed postoperative ileus and 
2 patients developed leakage from the anastomotic site, yet none of 
these patients died. The average follow-up period of the patients 
was 24±17 months. During the follow-up period, the number of 
patients who recurred after radical resection were 10 patients of 
the 27 patients (37%). Among the entire 29 patients, 8 patients died 
(27.6%).
2. The clinicopathological characteristics according 
to the disease at the time of the first operation
When comparing the RGC-B patient group and the RGC-M 
patient group, gender, the method of anastomosis at the first op-
eration, the tumor location, whether transfusion was performed, 
whether radical resection was performed, the histological classifica-
tion, the tumor size, recurrence and death did not show significant 
differences between the 2 groups. The age of the RGC-B patient 
group was higher than that of the RGC-M group (66±8 years 
vs. 58±10 years, respectively, P=0.023). It was observed that the 
interval from the first operation to the diagnosis of remnant gastric 
cancer for the RGC-B group was longer than that of the RGC-M 
patient group (36±6 years vs. 7±5 years, respectively, P＜0.001). 
The T stage of the RGC-B patient group was higher than that of 
the RGC-M group (P=0.003). The N stage of the RGC-B patient 
group was higher than that of the RGC-M patient group (P＜0.001). 
In addition, more lymphovascular invasion as well as perineural 
invasion were observed in the RGC-B patient group (P=0.021 and 
P=0.005, respectively). In regard to the TNM stage, similarly, the 
RGC-B patient group showed more advanced stages (P=0.003), yet 
the number of M stage patients of the two groups did not show a 
difference (Table 3).
3. Factors affecting the survival of the total pa-
tients
The patient age and gender, the initial gastric disease at the time 
of the first operation, the anastomosis method at the first operation 
and the interval from the first operation to the diagnosis of remnant 
gastric cancer did not affect the survival rate. In addition, the loca-
tion of tumor in the remnant stomach, whether or not transfusion 
was performed during the operation and the histologic classifica-
tion did not affect the survival rate. The N stage, lymphovascular 
invasion and perineural invasion between the RGC-B group and 
the RGC-M groups showed statistically significant differences, but 
Table 1. Clinicopathological characteristics of the 29 patients with 
RGC
Total number N=29
Age (years) Mean±S.D. 61±10
Sex Male 25 
Female 14
Interval* (years) Mean±S.D. 17±14.5
Curative resection (%) (+) 27 (93.1%)
(−) 2 (6.9%)
Retrieved lymph node Mean±S.D. 21±10
Combined resection (%) 12 (41.4%) 
Operation time (min) Mean±S.D. 248±93 
Hospital stay (days) Mean±S.D. 19±16 
Postoperative morbidity (%) 6 (20.7%)
Tumor size (mm) Mean±S.D. 46±36




Follow-up period (months) Mean±S.D. 24±17
Death (%)   8 (27.6%)
RGC = remnant gastric cancer; S.D. = standard deviation. *Interval 
between initial operation to diagnosis.






Recur  N (%) 2 (25%) 8 (44.1%)
Site of recurrence Liver  0 2
Lung 0 2
Peritoneum 0 4
Anastomotic site  2 0
Stage I 0 2
II 0 0
III 2 6Lee SB, et al.
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the survival rates did not show a difference. Among the 27 patients 
who underwent curative resection, 6 patients (22.2%) died. In the 
patient group that underwent palliative resection, 2 patients (100%) 
died, and a statistically significant difference was shown between 
the group who underwent curative resection and the group who 
underwent pallative resection (P＜0.001). Similarly, on comparing 
the mortality (of the T stage I and II patients (15.4%), the stage III 
patients (16.7%) and the IV patients (100%), the higher grade patients 
showed higher mortality, and a significant difference was seen (P
＜0.001)). (In regard to tumor size, the survival rate between tumors 
larger than 5 cm and less than 5 cm showed a statistically difference 
(P＜0.001)). In regard to the tumor size, based on 5 cm, the survival 
rate showed a statistically significant difference (P＜0.001). However, 
when multivariate analysis was performed on the factors that were 
statistically significant on the univariate analysis, all the factors were 
not statistically significant (Table 4, 5).
Table 3. Clinicopathological characteristics according to the initial gastric disease
Factor Benign (N=10) Malignancy (N=19) P-value
†
Age (years) Mean±S.D. 66±8 58±10 0.023
Sex Male/Female 8/2 17/2 0.592
Reconstruction 
 of initial operation
B-I 2   5 0.410
B-II 8 12
Roux-en-Y 0   4
Interval* (years) Mean±S.D. 36±6 7±5 <0.001
Tumor location Anastomotic site 4   8 0.322
Non-anastomotic site 6   7
Entire 0   4
Transfusion (+) / (−) 6/4 6/13 0.236
Curative resection (+) / (−) 8/2 19/0 0.111
T stage 1 / 2, 3, 4 0/10 11/8 0.003
N stage (+) / (−) 10/0 2/17 <0.001
M stage (+) / (−) 2/8 0/19 0.111
TNM stage I /  II, III, IV 0/10 11/8 0.003
Histology Diff  erentiated 4 13 0.236
Undiff  erentiated 6   6
Intestinal 4 11 0.450
Diff  use 6   8
Lymphovascular invasion (+) / (−) 8/2 6/13 0.021
Perineural invasion (+) / (−) 8 / 2 4/15 0.005
Tumor size (mm) Mean ± S.D. 46±10 45±19 0.394
Recur (+) / (−)  2/6
† 8/11 0.666
Death (+) / (−)  2/8 6/13 0.675
S.D. = standard deviation. *Interval between initial operation to diagnosis; 
†n=8.








Age (years) <60 15 4 0.9304
>60 14 4
Sex Male 25 8 0.3931
Female 4 0
Initial gastric disease Benign 10 2 0.5581
Malignancy 19 6
Reconstruction 
 of initial operation
B-I 5 2 0.1010
B-II 20 2
Roux-en-Y 4 4
Interval* (years) ≤15 18 6 0.4885
≥15 11 2
*Interval between initial operation to diagnosis.Remnant Gastric Cancer
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Discussion
The treatments for remnant gastric cancer include surgical treat-
ment, radiation therapy, chemotherapy and immunological therapy, 
which are all similar to that used for primary gastric cancer. None-
theless, surgery is known to be the only curative method. Generally, 
the surgical treatments include the complete resection of the remnant 
stomach and more than D2 lymphadenectomy.(5) In several reports, 
the rates of performing radical resection for remnant gastric can-
cer were diverse from 50~90%.(1,6,7) In our study, among the 29 
patients, 27 patients (93.1%) received total gastrectomy with more 
than D2 lymphadenectomy, and the rate was slightly higher than 
that of other studies. However, such results have the possibility 
of a selection bias by including only the patients for whom radi-
cal resection could be performed among all the patients diagnosed 
with remnant gastric carcinoma. Hu et al.(5) have reported that 
at the time of surgery for the remnant stomach cancer, the rate 
of the combined resection of adjacent organs could be increased 
because of the change of the pattern of lymph node metastasis due 
to previous surgeries and the adhesion of the adjacent organs. In 
other reports, similarly, the rate of the combined resection of ad-
jacent organs was reported as high as 40~70%.(8,9) We performed 
combined resection of adjacent organs in 41.4% of the cases, and 
similar findings were seen.
The interval from the first operation to the diagnosis of remnant 
gastric cancer was very different depending on the studies. This has 
generally been reported to be 22~27 years for the RGC-B patient 
group and that of the RGC-M group has been reported to be ap-
proximately 8.3~9 years.(1,2,10) In our study, similarly, the interval 
from the first operation to the diagnosis of recurrent gastric cancer 
for the RGC-B patient group was 36±6 years, and it was longer 
than the 7±5 years of the RGC-M group. Such a difference is 
generally considered to be due to the different mechanisms for the 
development of remnant gastric cancer for the two groups. In the 
RGC-B patient group, the irritation of the mucosa by the reflux of 
bile and pancreatic juice from the duodenum is considered to be a 
major factor for the development of remnant gastric cancer. On the 
other hand, in the RGC-M patient group, specific precancerous 
conditions are considered to be factors for the development of rem-
nant gastric cancer.(1,4,11) Therefore, the interval to the develop-
ment of remnant gastric cancer is longer, and more remnant gastric 
cancer develops at the anastomotic site in the RGC-B patient group 
than that in the RGC-M patient group.(1,4,6) However, in our 
study, the location of remnant gastric cancer of the RGC-B patient 
group and the RGC-M patient group did not show a great differ-
ence. Therefore, it is thought that other factors are present besides 
the irritation of the mucosa by the reflux of bile and pancreatic 
juice from the duodenum. Kaminishi et al.(12) suggested that due 
to the weakening of the mucosal defense capacity of the remnant 
stomach, which is caused by denervation after distal gastrectomy, 
the development of remnant gastric carcinoma may be increased. 
In addition, in our study, the average age of the RGC-B patient 
group was 66±8 years, which is the age that is prone to develop 
gastric cancer, and the possibility that age exerts effects on the de-
velopment of remnant gastric cancer and so remnant gastric cancer 
is developed in the area other than the anastomotic site should be 









Tumor location Anastomotic site 13 4 0.7623
Non-anastomotic site 12 4
Entire 4 0
Transfusion (+) 12 4 0.8498
(−) 17 4
Curative resection (+) 27 6 <0.001
(−) 2 2
T stage I, II 13 2 <0.001
III 12 2
IV 4 4
N stage (+) 12 4 0.8571
(−) 17 4
M stage (+) 2 2 <0.001
(−) 27 6
TNM stage I, II 15 2 0.0453
III, IV 14 6
Histology Diff  erentiated 17 4 0.1669
Undiff  erentiated 12 4
Intestinal 15 4 0.2072
Diff  use 14 4
Lymphovascular
 invasion




(+) 12 6 0.0917
(−) 17 2
Tumor size (cm) ≤5 23 4 <0.001
>5 6 4Lee SB, et al.
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considered.(13)
In addition, the RGC-B patient group and the RGC-M group 
showed a difference for the TNM stage. The RGC-B patient group 
showed a more advanced T stage as well as N stage compared to 
that of RGC-M patient group. This is thought to be due to the 
fact that regular follow-up such as endoscopy was not commonly 
performed in the RGC-B patient group, and so more advanced 
remnant gastric cancer was detected in many of these patients. 
Yet Kodera et al.(2) stated that in the patient group that underwent 
distal gastrectomy for malignant diseases, at the time of operation, 
lymphadenectomy was performed radically, and so lymph node 
metastasis would be relatively lower than that in the patient group 
that underwent operation for benign diseases.
It has been reported that the prognosis of patients with rem-
nant gastric cancer is generally poor and 5-year survival rate is 
40~60%. The follow-up period of our study was an average of 24
±17 months, the disease-free survival rate after curative resection 
was 62.9% and the survival rate of the total patients was 72.4%. Al-
though we obtained results similar to those of the previous reports, 
the follow-up period of our study was short and so the results of 
the long-term follow-up are required. It is known that the factors 
affecting survival rate are the TNM stage, whether or not radical 
resection was performed and tumor size. Hu et al.(5) have reported 
that the 5-year survival rate of the patient group that received 
curative resection was higher than that of the group that did not 
receive curative resection. In addition, in another study, the patient 
group with a lower TNM stage showed a 77% survival rate, which 
was higher than the generally reported 5-year survival rate for pa-
tients with remnant gastric cancer.(14) It is thought that the radical 
resection and low TNM stage resulted from the early detection of 
remnant gastric cancer, and so regular follow-up after distal gas-
trectomy may play an important role. Ojima et al.(15) performed a 
multivariate analysis on the factors that may affect the possibility of 
curative resection of remnant gastric carcinoma, and they suggested 
that the regular follow-up is the only factor affecting the possibility 
of achieving curative resection.
Based on our study, although the number of patients was small, 
we found that the disease stage as well as radical resection are very 
important for improving the survival rate of patients with remnant 
gastric carcinoma. Therefore,  appropriate follow-up observa-
tion after distal gastrectomy is very important for improving the 
survival rate of patients with remnant gastric cancer, regardless of 
the previous disease. After the detection of remnant gastric cancer, 
aggressive efforts when performing radical resection are required 
during the operation. 
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